home : staff [ mark scholz cv :: richard lam cv :: duke bahn cv :: ]
CURRICULUM VITAE
Mark C. Scholz, M.D. |
|
| PERSONAL INFORMATION: |
| E-mail Address |
mark@prostateoncology.com |
| Foreign Languages |
Spanish |
| Business Address |
4676 Admiralty Way
Suite # 101
Marina del Rey, CA 90292 |
| Business Telephone |
(310) 827-7707 |
| Business Fax |
(310) 574-4002 |
| Licensure |
California: G52827 |
| Board Certification |
Internal Medicine - 1986
Medical Oncology - 1989 |
|
| EDUCATION: |
| High School |
Corona Del Mar 1969-1973 |
| College/University |
Orange Coast College 1973-1974
University of Southern California 1974-1976 |
| Medical School |
Occidental College 1976-1978
Creighton University class of 1983 |
| Internship |
Internal Medicine 1983-1984
LAC-USC Medical Center |
| Residency |
Internal Medicine 1984-1986
LAC-USC Medical Center |
| Fellowship |
Medical Oncology 1986-1988
LAC-USC Medical Center
Chief Fellow, 1987-1988 |
|
| PROFESSIONAL BACKGROUND: |
| Academic Appointments |
Clinical Assistant Professor of Medicine, U.S.C. |
| Administrative Responsibilities |
Oncology Director, Daniel Freeman Medical Center, 1996-2001
Co-Founder & Past President of Prostate Cancer Research Institute 1996-1999: Presently on the Board of Directors
Oncology Director Medical Center of North Hollywood 1993-1994
Oncology Director, Mullikin Medical Center, Cerritos, Ca. 1988-1990 |
| Present Employment |
Medical Director
Prostate Oncology Specialists, Inc.
Marina del Rey, California
Expert Oncology Witness
Case Reviews: 60 cases
Depositions: 16 cases
Court Testimony: 7 cases
|
| Editorial Responsibilities |
Consultant:
Journal of Urology
Cancer
Clinical Genitourinary Cancer
Editor PCRI Insights Newsletter
Task Force for Androgen
|
| Other Commitments |
Steering Committee of the Bereavement Project at Concordia University
Steering Committee for Minority Involvement in Clinical Trials at USC |
|
SOCIETY MEMBERSHIPS:
Los Angeles County Medical Association
California Medical Society
Medical Oncology Society of S. California
American Medical Society
American Society of Clinical Oncology
American Society of Therapeutic Radiology
American Urological Association
American College of Physicians
American Medical Association
Affiliate Member AUA
European Association of Urology |
|
HOSPITAL AFFILIATIONS:
St. John's Hospital, Santa Monica
Centinela Freeman, Memorial Campus
Centinela Freeman, Marina Campus
Motion Picture Hospital, Canoga Park
Los Angeles County USC Medical Center |
|
| EDUCATIONAL SERVICES: |
| CME Lectures: |
PSA Nadir Predicts Prostate Cancer Progression San Diego March 2006
Ketoconazole for Treating Prostate Cancer Washington DC June 2005
Management of Bone Integrity Washington DC June 2005
Newly Diagnosed Prostate Cancer Los Angeles November 2004
Adjuvant Hormone Blockade with Radiation Universal City January 2004
Relapsed Prostate Cancer Universal City January 2004
Hormone Blockade for Prostate Cancer Burbank September 2003
Chemotherapy for Prostate Cancer Burbank September 2003
Androgen Insensitive Prostate Cancer Hilo, Hawaii November 2002
PCRI Conference Moderator Los Angeles October 2002
Treatment of Hormone Resistance Whittier September 2002
Hormone Blockade for Early PC Los Angeles April 2001
PSA Nadir After Hormone Blockade Vancouver, Canada March 2001
Hormone Blockade Update LA Radiological Society January 2000
Intermittent Hormone Blockade Long Beach Convention Center July 1999
Proscar & Intermittent Hormone Blockade AUA Podium presentation May 1999
Newly Diagnosed Prostate Cancer Daniel Freeman Marina October 1998
Staging Prostate Cancer Daniel Freeman Marina May 1998
Prostate Cancer Overview Daniel Freeman Memorial Hospital Nov. 1997
Early Hormonal Therapy Santa Monica-UCLA Medical Center October 1997
Prostate Cancer Screening Daniel Freeman Hospital, Marina del Rey July 1997
Prostate Cancer Update St. Joseph’s Hospital Burbank, Ca. March 1997
Breast Cancer Update Sherman Oaks Hospital Sherman Oaks, Ca. January 1993
|
| Community Lectures: |
Prostate Cancer Update Santa Monica California June 2006
A New Perspective: Look Before You Leap Fullerton California February
2006
Testosterone Independent Prostate Cancer Marina del Rey California January
2006
PSA Relapse after Surgery or Radiation. Honolulu, Hawaii November 2005
My Prostate Cancer is Back. What Now? Las Vegas, Nevada October 2005
Don’;t Let Prostate Cancer Ruin Your Life El Segundo, Ca September
2005
Primary Androgen Deprivation Los Alamos NM April 2005
Cancer de Prostata Recien Diagnosticada November 2004
Newly Diagnosed Prostate Cancer Lancaster May 2004
Taxotere for Prostate Cancer Bakersfield April 2004
Recurrent Cancer after Radiation San Jose February 2004
Treating Relapsed Prostate Cancer Fullerton January 2004
Treatment of Rising PSA Las Vegas November 2003
Recurrent Prostate Cancer Maui, Hawaii November 2003
Relapsed Prostate Cancer San Diego October 2003
Prostate Cancer Overview Irvine August 2003
Androgen Independent Prostate Cancer Marina del Rey May 2003
Treatment of Hormone Resistance Phoenix March 2003
Hormone Blockade Side-effects Bakersfield March 2002
Prostate Cancer Staging Las Vegas January 2002
Watchful Waiting for Prostate Cancer Ventura September 2001
Treatment for Hormone Resistant Prostate Cancer Oxnard June 2001
Predictors of Hormone Resistance Marina del Rey March 2001
Hormone Blockade for Early Stage Prostate Cancer Bakersfield December 2000
Hormone Blockade, How Long Does it Last? Phoenix November 2000
Prostate Cancer overview Santa Monica October 2000
Early Stage Prostate Cancer Marina del Rey September 2000
Hormone Resistant Prostate Cancer Riverside June 2000
Newly Diagnosed Prostate Cancer Palm Springs April 2000
New Approaches to Prostate Cancer Marina del Rey March 2000
Treatment of Early Stage Prostate Cancer Santa Monica March 2000
Criteria for Intermittent Hormone Blockade San Diego December 1999
PSA Relapse after Surgery or Radiation Bakersfield October 1999
New Developments in Prostate Cancer Hacienda Heights May 1999
Nutrition and Prostate Cancer Long Beach April 1999
The Androgen Deprivation Syndrome Laguna Beach February 1999
Prostate Cancer Overview Inglewood November 1998
Prostate Cancer Staging Daniel Freeman Marina Hospital Sept. 1998
Alternative Medicine Approaches Marina del Rey May 1998
Hormone Blockade for Early Stage Prostate Cancer Redondo Beach May 1998
Chemotherapy for Prostate Cancer Riverside Medical Foundation Oct. 1997
The Influence of Grief on Health The Lutheran Equipping Conference Sept. 1997
Adjuvant Chemotherapy Long Beach Memorial Hospital August 1997
Intermittent Hormone Blockade Brotman Hospital Culver City June 1997
Prostate Cancer Prevention Monarch Beach June 1997
Prostate Cancer Treatment Options Santa Monica Hospital May 1997
Hormone Blockade Cottage Hospital Santa Barbara April 1997
Advanced Hormone Therapy Loma Linda Hospital Loma Linda April 1997
Neoadjuvant Hormone Blockade Bakersfield Medical Center November 1996
Early Hormone Therapy Prostate Support Group Fullerton, Ca. June 1996
Cancer Overview Brotman Wellness Center Culver City, Ca. May 1996
Treatment With Proscar San Diego Support Group San Diego, Ca. Jan. 1996
Prostate Cancer Treatment Options Glantz Auditorium Culver City May 1995
Therapy for Stage D2 Prostate Cancer Culver City October 1995
Treatment of Melanoma Medical Center of North Hollywood Oct. 1993
Nutrition and Cancer Medical Center of North Hollywood March 1993
|
|
CONFERENCES:
Moderator for PCRI Regional Conference November 2004 |
|
AWARDS:
Best Poster Western AUA 2003: PSA Nadir Greater than 0.1 on Combined Hormone Blockade Predicts the Early Development of Androgen Independent Prostate Cancer. Mark C. Scholz, Tom Trilling, Stan A. Brosman, Brad W. Guess, Henry J. Johnson, Richard Y. Lam
Best Poster AUA 1997: Anemia Associated with Androgen Deprivation in Prostate Cancer Patients on Combination Hormone Blockade. Strum SB, McDermed JE, Scholz M.C.
Best Poster AUA 1997: Anemia Associated with Androgen Deprivation in Prostate Cancer Patients on Combination Hormone Blockade. Strum SB, McDermed JE, Scholz M.C. |
|
BIBLIOGRAPHY:
Scholz, M., Jennrich, R., Strum, S., Johnson, J., Guess, B., Lam, R., Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period. The Journal of Urology, 2006
Guess, B., Scholz, M., Lam, R., Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer. Seminars in preventative and Alternative Medicine, 2006
Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R, Long-Term Outcome in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone. Journal of Urology Vol. 173: 1947, 2005
Scholz, M., Lam, R., Guess, B., Blum, R., When Should You Start Treatment with Ketoconazole? PAACT Vol. 21 #4, 2005
Scholz, M., Blum, R., Can Diet Really Control Prostate Cancer? PCRI Insights Vol. 9, #1 2006
Scholz, M., Blum, R., Who is Really at Risk for What? PCRI Insights Vol. 8, #2 2005
Scholz, M. The Best Treatment for Prostate Cancer. PCRI Insights Vol. 7, #3 2004
Guess B, Scholz M, Strum S, Lam R, Johnson H, Jennrich R,: Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer. Prostate Cancer and Prostatic Diseases Vol. 6: 301-304 2003
Guess, B., Jennrich, R., Johnson, H., Redheffer, R., Scholz, M., Using Splines to Detect Changes in PSA Doubling Times. Prostate Vol. 54 #2: 88-94, 2003
Scholz, M. Prostate Cancer Battle: Its Strictly Your Decision Chapter #11 “New Approaches to Prostate Cancer Treatment 1st Books Library March 2002
Scholz, M. Prostate Cancer Battle: Its Strictly Your Decision Chapter #10 “Early Hormone Blockade for Men Suitable for Local Therapy” 1st Books Library March 2002
Scholz, M., Lam, R., Guess, B., Anti-androgen Monotherapy for Prostate Cancer. PAACT Cancer Communication Letter Volume 18 #2
Scholz, M. Strum, S. Berrios, F. Leibowitz, B. Guess, B. Low-Dose Weekly Docetaxel in Elderly Men with Prostate Cancer. Advances in Prostate Cancer Vol. 5, No. 3 2001
Guess, B. Scholz, M. Re: Failure to Achieve Castrate Levels of Testosterone During Luteinizing Hormone Releasing Hormone Agonist Therapy: The Case for Monitoring Serum Testosterone and A Treatment Decision Algorithm J. Urol., Vol. 164: 726-729, 2000
Scholz, M., Strum, B. PSA Nadir after starting Hormone Blockade Letter to the Editor J. Urol., Vol. 162: 293-306, 1999
Strum, S. Scholz, M. McDermed, J. Intermittent Androgen Deprivation in Prostate Cancer Patients; Factors Predictive of Prolonged Time off Therapy The Oncologist Vol. 5 2000
Scholz M.C., Strum S.B. Recovery of Erectile Function while on Hormone Blockade using Sildenafil (Viagra) Letter to the Editor J. Urol., 161: 1914-1915, June 1999
Strum SB, McDermed JE, Scholz M.C., Johnson H & Tisman G: Anemia associated with androgen deprivation (AAAD) in prostate cancer patients receiving combination hormone blockade. Brit J Urol. June 1997
Gill, I., Gurglianone, P., Grunberg, S.M., Scholz, M.C., and Muggia, F.M., High Dose Intensity of Cisplatin and Etoposide in Adenocarcinoma of Unknown Primary. Anticancer Research, II, 1231, 1991 |
|
ABSTRACTS & POSTERS:
M. Scholz, R. Lam, R. Jennrich, S. Strum, B. Guess, H. Johnson, Ultra-sensitive
PSA nadir on testosterone-inactivating-pharmaceuticals accurately predicts
early prostate cancer progression. Prostate Cancer Symposium Abstract
#40, 2006
R. Lam, M. Scholz, B. Guess, T. Trilling, H. Goodman, Oral Bisphosphonates
fail to prevent bone loss form androgen deprivation therapy in men with
prostate cancer. Prostate Cancer Symposium Abstract #122, 2006
S. Strum, M. Scholz, Optimized imaging in prostate cancer is absent 95%
of the time at diagnosis or PSA recurrence. Prostate Cancer Symposium
Abstract #68, 2006
M. Scholz, R. Lam, S. Strum, H. Johnson, T. Trilling R. Jennrich. Intermittent
use of Testosterone-Inactivating-Pharmaceuticals using Finasteride during
Testosterone-Recovery Prolongs the Time-Off-Period. Multidisciplinary
Prostate Cancer Symposium abstract #153 2005
R. Lam, M. Scholz, B. Guess, J. Mahoney, H. Johnson, T. Trilling, H. Goodman Oral bisphosphonates for the prevention of androgen deprivation therapy associated bone loss ASCO Abstract #4749 2004
M. Scholz, J. Johnson, B. Guess, R. Lam Extent of Disease on Bone Scan, Baseline Alkaline Phosphatase, and 80% Decline in PSA are the Best Indicators Predicting Long Term Survival in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone. Western AUA 2003
M. Scholz, B. Guess, R. Lam, Calcitriol Restores Docetaxol Anticancer Activity in Men with Androgen Independent Prostate Cancer Who Previously Progressed on Docetaxol. Western AUA 2003
M Scholz Guess, B. Barrios, F. Strum, S. Leibowitz, B. Low-dose Single-Agent Weekly Taxotere is Effective and Well Tolerated in Elderly Men with Prostate Cancer. ASCO Abstracts 2001
M. Seltzer, S Strum, M Scholz, A Belldegrun, N Satyamruthy, Comparison of whole body C-11 acetate and FDG PET in patients with prostate cancer Nuclear Medicine Abstracts 1999
Scholz, M., Strum, S., Mittelman, P., High-Dose Ketoconozole and Hydrocortisone for Hormone Refractory Prostate Cancer. ASCO abstracts 1999
M. Scholz, S. Strum, J. McDermed. Intermittent Androgen Deprivation (IAD) with Finasteride (F) During Induction and Maintenance Permits Prolonged Time off IAD in Localized Prostate Cancer (LPC). Presented by Dr. Scholz. The Journal of Urology, April 1999.
M. Scholz, S. Strum, Phase II Trial of Weekly Low-Dose Taxotere in the Treatment of Patients with Hormone Refractory Prostate Cancer ASCO Abstracts 1999
S. Strum, M. Scholz, A Phase II Trial of Taxotere and Emcyt for Metastatic Prostate Cancer ASCO Abstracts 1999
M. Scholz, S. Strum, L. Madsen, J. McDermed. Intermittent Androgen Deprivation (IAD) Therapy for Prostate Cancer: PSA Response on Cycle 1 Can Predict Response on Subsequent Cycles. Proceedings of ASCO Volume 18 1999, Atlanta, Georgia.
M. Scholz, S. Strum, J. McDermed, L. Madsen. Intermittent Androgen Deprivation (IAD) with Finasteride Given During the Induction and Maintenance Periods Results in Prolonged Time off IAD in Patients with Localize Prostate Cancer. Proceedings of ASCO Volume 18 1999, Atlanta, Georgia
Scholz M.C., Strum S.B, McDermed JE: A phase II trial of Taxotere (t)/Estramustine (e) combination in patients (pts) with prostate cancer (pc). Accepted for publication at the ASCO meeting May 19th, 1998, Los Angeles, CA.
Scholz M.C., McDermed JE, Strum SB: Intermittent Hormone Blockade (IHB): Optimal Induction Duration and Predictive Factors for Prolonged time Off Hormone Blockade (HB). Poster Presentation for the Xth International Congress on Hormonal Steroids, June 18th, 1998, Quebec City.
Scholz M.C., McDermed JE, Strum, SB: Combined Hormone Blockade (CHB) Induction and Finasteride Maintenance (FM) Permits Discontinuation of CHB for Prolonged Periods in Patients with Low-Volume (LV) Prostate Cancer (PC). Poster Presentation for the Xth International Congress on Hormonal Steroids, June 18th, 1998, Quebec City..
Tisman G, Strum SB, Scholz M.C., et al: Computer assisted, tumor volume-based decision making in expectant management of early stage prostate cancer. Abstract #1480, AUA 1997.
Scholz M.C., Strum SB, McDermed JE, Tisman G, Johnson H: Prolonged non-detectable PSA (NDPSA) in patients (PTS) receiving combination hormone blockade (CHB) allows for discontinuation of androgen blockade. Abstract #1478, AUA 1997.
Strum, SB, Scholz M.C. & McDermed JE: The Androgen Deprivation Syndrome: the incidence and severity in prostate cancer patients receiving hormone blockade. Accepted for poster presentation at the ASCO meeting May 19th, 1998, Los Angeles, CA.
Strum SB & Scholz M.C., Intermittent hormone blockade (IHB) in prostate cancer (PC) patients: Duration of non-detectable PSA (NDPSA) on androgen blockade relates to time off treatment. Abstract, 7th International Congress on Anti-Cancer Treatment, February 3-6, Paris, France, 1997.
Tisman, G, Strum SB, Scholz M.C., et al: Pre-therapy prediction of the duration of post-therapy non-detectable PSA for prostate cancer patients considering intermittent combine hormonal blockade. Proc Amer Soc Clin Oncol 16: 346a, 1997.
Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., nd Johnson, H., Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO). AUA abstract #1483, 1997.
Strum SB, McDermed JE, Scholz M.C.,et al: Anemia associated with androgen deprivation (AAAD) in prostate cancer (PC) patients (PTS) receiving combination hormone blockade (CHB). Proc Amer Soc Clin Oncol 16:345a, 1997.
Strum SB, McDermed J, Scholz M.C., et al: Time to non-detectable (TTND) PSA in prostate cancer (PC) patients on combination hormone blockade (CHB) predicts favorable outcomes. Proc Amer Soc Clin Oncol 16: 345a, 1997.
Strum SB, McDermed JE, Scholz M.C., Tisman G, Johnson H: Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO). J Urol 157:232 1997. (Abstract).
Tisman, G., Strum, S.B., Scholz, M.C., and McDermed, J., Pre-therapy prediction of the duration of post-therapy non-detectable PSA for prostate cancer patients considering intermittent combined hormone blockade by use of computerized neural net modeling. Abstract submitted to ASCO, 1997.
Strum, S.B., Scholz, M.C. & Strum, M. Prolonged non-detectable PSA (NDPSA) in PC patients treated with androgen deprivation may allow for discontinuation of hormone blockade. International Symposium on Recent Advances in Diagnosis & Treatment of Prostate Cancer, Quebec City, September 21-23, 1995 (Poster Presentation).
Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and Johnson, H., Intermittent hormone blockade (IHB) in prostate cancer (PC) patients (PTS): Duration of non-detectable PSA (NDPSA) on androgen blockade relates to time off treatment. 7th International Chemotherapy Congress abstract, 1997.
Strum, S.B. McDermed, J.E., Scholz, M.C., Johnson, H.J., and Tisman, G., Anemia associated with androgen deprivation (AAAD) in prostate cancer (PC) patients (PTS) receiving combination hormone blockade (CHB). Abstract submitted to ASCO 1997.
Strum, S., McDermed, J., Scholz, M.C., and Tisman, G., time to non-detectable (TTND) PSA in prostate cancer (PC) patients on combination hormone blockade (CHB) predicts favorable outcomes. Abstract submitted to ASCO, 1997
Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and Johnson, H., Anemia associated with androgen deprivation in prostate cancer (PC) patients on combination hormone blockade (CHB). AUA abstract #1481, 1997.
Tisman, G., Strum, S.B., Scholz, M.C., McDermed, J.E., and Johnson, H., Computer-assisted, tumor volume-based decision making in expectant management of early stage prostate cancer. AUA abstract #1480, 1997.
Scholz, M.C., Grunberg, S., Muggia, F.M., Rosen, P., and Leishman, L., Phase I Study of TMCA. AACR Abstracts
Scholz, M.C., Strum, S.B., McDermed, J.E., Tisman, G., and Johnson, H.,
Prolonged non-detectable PSA (NDPSA) in patients (PTS) receiving combination
hormone blockade (CHB) allows for discontinuation of androgen blockade.
AUA abstract #1478, 1997.
Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H., Guess, B.G., Lam,
R.Y., Intermittent Use of Testosterone Inactivating Pharmaceuticals Using
Finasteride Prolongs the Time Off Period. J Urol 175:1673 2006. |
|
EDUCATIONAL BOOKLETS & BROCHURES:
Adjuvant Testosterone Inactivating Pharmaceuticals
Avodart or Proscar for the Treatment of Prostate Cancer
Anti-androgen Monotherapy
Bisphosphonates: Preventing Cancer Spread to the Bones
Family History of Prostate Cancer
How Prostate Cancer Can Extend Your Life
Introduction to Testosterone Inactivating Pharmaceuticals
Introduction to the Treatments for Newly-Diagnosed Prostate Cancer
Osteoporosis
Preventing the Side Effects of Testosterone Inactivation Pharmaceuticals
Surgery vs. Seeds vs. IMRT
Taxotere
The Best Treatment for Prostate Cancer
The PSA Blood Test for Diagnosing Prostate Cancer: Arguments Pro and Con
Newly Diagnosed Prostate Cancer: Evaluating the Options Part I
Newly Diagnosed Prostate Cancer: Evaluating the Options Part II
Newly Diagnosed Prostate Cancer: Evaluating the Options Part III
Adjuvant Testosterone Inactivating Pharmaceuticals
So You Have an Elevated PSA
Recently Diagnosed Prostate Cancer
Explanation of Laboratory Tests
TIP for Early Stage Disease
The Best Treatment for Prostate Cancer
Hormone Blockade for Early Stage Prostate Cancer |
Clinical Trials in Progress for Prostate Cancer:
Intermittent Hormone Blockade with High dose Casodex
Thalidomide and Leukine for men with PSA relapse
Androgen replacement for prostate cancer patients with testicular failure
Prevention of Bone Loss with Oral Bisphosphonates
Atrasentin for Stage D2 Prostate Cancer
|
|
|
|
|
